Announcement of Renfu Pharmaceutical Group Co., Ltd. on the performance of commitments

Securities Code: 600079 Securities Code: People's Pharmaceutical Number: Lin 2014-046 The announcement of the performance of the commitment series by The company Pharmaceutical Group Ag special notice
the board of directors of the company and all directors to ensure that the contents of this announcement do not contain any false records, misleading statements or major omissions, and its contents are responsible for the authenticity, accuracy and completeness of the company's shares and related trends
according to the China Securities Regulatory Commission's Guidelines for the Supervision of Listed Companies No 4 - The Actual Controllers, Shareholders, Related Parties, Acquirers and Commitments and Fulfillments of Listed Companies (CSRC Bulletin No 55, "Regulatory Guidelines") and the Notice of the Hubei Regulatory Bureau of the China Securities Regulatory Commission on Further Ingiving The Commitment and Performance of Supervision of Listed Companies in the Jurisdiction ( Referred to as "Human Fu Medicine" or "Company") as of this announcement date has not yet fulfilled the commitment matters are listed as follows: commitment background
commitment type Commitment party commitment content commitment content time and term
whether to fulfill the time and term
whether the timely and strict implementation of the related
to the stock reform the limited sale of shares Wuhan Contemporary Technology Industry Group Co., Ltd 2, after the expiration of the 1st commitment, The number of shares sold through the Shanghai Stock Exchange shall not exceed 15% of the number of shares held each year, and the shares shall be sold through the Shanghai Stock Exchange for sale through the Shanghai Stock Exchange at a price of 185% (6.00 yuan) below the arithmetic average of the 30 trading days prior to June 17, 2005 commitment time: August 2005 commitment period: Permanent is is the commitment related to refinancing
share limit Wuhan Contemporary Technology Industry Group Co., Ltd the company's largest shareholder Wuhan Contemporary Technology Industry Group Co., Ltd in 2013 when the company issued shares in a non-public offering of shares commitment: this subscription of shares from the end of the company's non-public offering within 36 months commitment period: 3 years
is is the the commitment related to refinancing
the limited sale of shares
Huaxia Fund Management Co., Ltd., Caitong Fund Management Co., Ltd., Castrol Fund Management Co., Ltd.
Huaxia Fund Management Co., Ltd., Caitong Fund Management Co., Ltd., CastroL Fund Management Co., Ltd., Castro Fund Management Co., Ltd in the company's 2013 non-public issue of shares commitment: the shares subscribed to the Company within 12 months from the end of the end of this non-public offering commitment period: 1 year is is the commitment related to refinancing
profit forecast and compensation
Wang Wei, Yan Lanfeng, Han Xiuhua, Ding Jie, Wang Fujun
, Wang Wei, Yu Lanfeng, Han Xiuhua, Ding Jie, Wang Fujun signed with the company "equity transfer" The contract promises: Beijing Barry Medical Devices Co., Ltd in 2012, 2013 and 2014 audited net profit of not less than 116.4 million yuan, 139.7 million yuan, 167.6 million yuan If the above commitment performance is not achieved, the above five natural person shareholders shall compensate the Company for the corresponding 80% share of the share, the annual amount of compensation shall be calculated as follows: the amount of compensation ( the amount of the underlying asset as of the end of the current period cumulative net profit - the amount of the underlying asset as of the end of the current period cumulative net profit) commitment period: 3 years is
other to avoid competition and regulate related transactions
Wuhan Contemporary Technology Industry Group Co., Ltd (4) to integrate competitive business into Human Medicine to operate ; The Company undertakes not to harm the legitimate rights and interests of The Company and other shareholders of People's Pharmaceutical Company and People's Medicine through related transactions commitment period: permanent is is other avoid competition and regulate related transactions
Aluming (4) will be competitive business into the operation of Human Fu Medicine ; I warrant that the legitimate rights and interests of The Company and other shareholders of People's Fu Pharmaceutical Company and Renfu Pharmaceutical stoist the legitimate rights and interests of The Company and Other Shareholders of People's Medicine through related transactions commitment period: Permanent is
a refinancing-related commitment
other Wuhan Contemporary Technology Industry Group Co., Ltd the largest shareholder Wuhan Contemporary Technology Industry Group Co., Ltd committed not to participate directly or indirectly in the subscription of HuitianFu Fund Management Co., Ltd and Henyep Global Fund Management Co., Ltd for the 2014 non-public issuance of A-share son son-a-public a-share asset management plan products (i.e., Huitian Fu-Advantage Pharmaceutical Enterprise commitment period: Permanent is is the of refinancing-related commitments
other company directors, supervisors, senior
managers commitment not directly or through any indirect means to participate in the subscription of Huitian Fu Fund Management Co., Ltd and Henyep Global Fund Management Co., Ltd for the 2014 non-public issuance of A-shares of the asset management plan products (i.e., HuitianFu-Advantage Pharmaceutical Enterprise S commitment period: permanent is is the Company does not have the commitment to meet the regulatory guidelines and the non-compliance of the commitment this announcement People's Fu Pharmaceutical Group Co., Ltd Board of Directors June 21, 2014 source Shanghai Securities News) click to enter the "Share Friends Association" to participate in the discussion